PER-012-08
已完成
未知
PHASE II STUDY IN PATIENTS WITH LOCALLY ADVANCED GASTRIC CANCER OR GASTROESOPHAGEAL ADENOCARCINOMA TREATED WITH IRINOTECAN / CISPLATINUM INDUCTION, POTENTIALLY CURATIVE SURGERY WITH INTRAPERITONEAL ADJUSTMENT FLOXURIDINE / CISPLATINUS FOLLOWED BY CAPECITABINE.
ew York University School of Medicina,0 个研究点目标入组 0 人2008年5月27日
概览
- 阶段
- 未知
- 干预措施
- 未指定
- 疾病 / 适应症
- -C169 Stomach, unspecified
- 发起方
- ew York University School of Medicina,
- 状态
- 已完成
- 最后更新
- 2年前
概览
简要总结
暂无简介。
研究者
入排标准
入选标准
- •Patients with isolated disease My potentially resectable, for example, hepatic metastasis, omentum compromise, peritoneal implants or distal intraperitoneal lymph nodes with cancer mestastases, may be eligible based on a strictly individual evaluation.
- •Both men and women\> 6 \= to 18 years of age with an ECOG activity status of 0\-2, members of any ethnic group and minorities.
- •Patients with no other invasive malignancy, with properly treated basal cells or squamous cell skin cancer, free for 5 years or more of in\-situ cervical cancer or other in\-situ cancer.
- •Since immunity deficiency increases the risk of terminal infections when aggravated by suppressive bone marrow therapy, patients should be without active or uncontrolled infection including HIV.
- •Patients without psychiatric disorders that could interfere with their consent and / or follow\-up of the protocol.
- •An adequate stock of bone marrow (absolute neutrophil count\> or \= 1500 / mmL, thrombocytes\> or \= 100000 / mmL, hemoglobin\> or \= 9 gm / dL).
- •Preserved hepatic and renal function (total serum bilirubin \<2 mg / dL, SGOT / SGPT or \= 50 mL / min) are required. The creatinine clearance must be normalized for a BSA of 1\.73 M2\. The prothrombin time, partially activated thromboplastin time, and thrombin time should be within the range of normal values.
- •Since the chemotherapeutic agents to be used are known or suspected of being teratogenic or with other adverse effects, women should not be pregnant or lactating. All women with reproductive potential should have a blood test or urine study within 2 weeks before registration to rule out pregnancy. All patients of reproductive age can not participate unless they agree to use an effective medically acceptable method of contraception.
- •Patients without diagnosis of Gilbert´s disease and a bilirubin level\> or \= 2\.0 mg / dL, given that these patients may have excessive toxicity to CPT\-11\.
- •No severe reaction prior to fluoropyrimidine therapy or known hypersensitivity to 5\-FU, Capecitabine (Xeloda) is contraindicated in patients with acute renal impairment, ie, creatinine clearance below 30 mL / min, determined by the Cockroñ\- Gault as shown in section 5\.5\.5 (i). In patients with moderate renal impairment (creatinine clearance 30\-50 mL / min), which develops during the course of adjuvant treatment with Capecitabine, the dose is reduced to 75% of the initial dose.
排除标准
- •Patients who fail (i) systemic induction therapy for PD, or (ii) potentially curative surgery, or (iii) IP / systemic adjuvant therapy for disease recurrence, are excluded from additional protocol treatment (see 7\. Evaluation during the treatment, and 8\. Post\-Treatment Evaluation). Patients who leave the protocol can undergo surgery if the tumor is locally resectable, and can be treated with a 5\-FU\-based regimen or other appropriate treatment.
- •The development of complications in the course of treatment of the protocol secondary to the tumor, surgery or therapy, which require surgical intervention such as gastro\-intestinal obstruction, bleeding, perforation, or complications that prevent IP or systemic chemotherapy.
- •Unacceptable toxicity that does not respond to dose modification and / or recommended medication.
- •Intercurrent diseases not related to cancer that prevent continuation of therapy or regular follow\-up of the patient, as well as other changes in the patient´s condition that, in the opinion of the PI, make subsequent treatment unacceptable.
- •Withdrawal of patient´s consent.
结局指标
主要结局
未指定
相似试验
进行中（未招募）
不适用
A Phase II study in patients with locally advanced pancreatic carcinoma:ARC-II – Akt-inhibition by Nelfinavir plus chemoradiation with gemcitabine and cisplatin - ARC-II in locally advanced pancreatic carcinomaborderline resectable or unresectable pancreatic carcinomaMedDRA version: 14.1Level: PTClassification code 10033611Term: Pancreatic carcinoma non-resectableSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 14.1Level: LLTClassification code 10033600Term: Pancreatic adenocarcinoma non-resectableSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 14.1Level: LLTClassification code 10033606Term: Pancreatic cancer non-resectableSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)Therapeutic area: Diseases [C] - Cancer [C04]EUCTR2008-006302-42-GBThe University of Oxford49
进行中（未招募）
1 期
Ipilimumab, nivolumab and tocilizumab in pretreated patients with advanced pancreatic cancer.Pretreated patients with advanced pancreatic cancer.MedDRA version: 21.1Level: LLTClassification code 10033605Term: Pancreatic cancer metastaticSystem Organ Class: 100000004864MedDRA version: 21.0Level: LLTClassification code 10033606Term: Pancreatic cancer non-resectableSystem Organ Class: 100000004864MedDRA version: 21.0Level: LLTClassification code 10033607Term: Pancreatic cancer recurrentSystem Organ Class: 100000004864Therapeutic area: Diseases [C] - Cancer [C04]EUCTR2019-004438-40-DKDepartment of Oncology, Herlev & Gentofte Hospital30
已完成
不适用
Irinotecan/Cisplatin, Potentially Curative Surgery With or Without Floxuridine, Followed by Capecitabine for Stomach and Gastro-esophageal Junction (GEJ) Cancers-C16 Malignant neoplasm of stomachMalignant neoplasm of stomachC16PER-160-08ew York University School of Medicina,
已完成
2 期
Randomized phase II study of clinical effects of ghrelin the perioperative period of esophagectomy with gastric tube reconstruction.Esophageal cancerJPRN-UMIN000007077Department of Gastroenterological Surgery, Department of Surgery, Graduate School of Medicine, Osaka University40
已完成
2 期
Randomized phase II study of clinical impact of ghrelin after esophagectomy with gastric tube reconstructioJPRN-UMIN000003298Department of Gastroenterological Surgery, Department of Surgery, Graduate School of Medicine, Osaka University20